Table 1.
Clinic or pathological parameter.
| Mean age at diagnosis (years) | 50.8 (27–71) |
| Menopausal status | N=325 (%) |
| Pre | 170 (52.3) |
| Post | 155 (47.7) |
| Clinical stage | |
| I | 54 (16.6) |
| II | 131 (40.3) |
| III | 140 (43.1) |
| Tumor size at baseline | |
| T1 | 210 (64.6) |
| T2 | 95 (29.2) |
| T3 | 17 (5.2) |
| T4 | 3 (1.0) |
| Node status at baseline | |
| − | 34 (10.5) |
| + | 291 (89.5) |
| Breast cancer subtype | |
| HR+ | 123 (37.8) |
| HER2+ | 136 (41.8) |
| Triple negative | 66 (20.4) |
| Curative effect | |
| PCR | 67 (20.6) |
| NPCR | 258 (79.4) |
| PD | 40 (12.3) |
HR+ – hormone receptor positive; HER2+ – human epidermal growth factor receptor 2 positive; PCR – pathological complete response; NPCR – non-pathological complete response; PD – progressive disease.